Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H4F8
UPID:
SMOC1_HUMAN
Alternative names:
Secreted modular calcium-binding protein 1
Alternative UPACC:
Q9H4F8; A8K1S3; B2R7P5; Q96F78
Background:
SPARC-related modular calcium-binding protein 1, also known as Secreted modular calcium-binding protein 1, is pivotal in eye and limb development. It is believed to play a crucial role in osteoblast differentiation, highlighting its importance in skeletal formation.
Therapeutic significance:
Linked to Ophthalmoacromelic syndrome, a rare condition characterized by eye and limb anomalies, understanding the role of SPARC-related modular calcium-binding protein 1 could open doors to potential therapeutic strategies.